Screener
Zymeworks ZYME R&D
R&D at other companies
Segments
By segment
Other financials
Where this comes from
Reported directly by Zymeworks in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.
The source filing: Zymeworks’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:11 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001937653-26-000047
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Revenue | ||||
| Research and development collaborations | $4,590 | $48,726 | $6,998 | $75,836 |
| Operating expenses: | ||||
| Research and development | 27,435 | 34,449 | 61,892 | 70,187 |
| General and administrative | 19,335 | 14,951 | 34,404 | 31,936 |
| Total operating expenses | 46,770 | 49,400 | 96,296 | 102,123 |
| Loss from operations | (42,180) | (674) | (89,298) | (26,287) |
| Other (expense) income: |
Item 1. Financial Statements
FAQ
- What is Zymeworks's R&D?
- Zymeworks (ZYME) reported R&D of $27.44M in Q2 2026.
- How has Zymeworks's R&D changed year-over-year?
- Zymeworks's R&D decreased by 20.4% year-over-year, from $34.45M to $27.44M.
- What is the long-term trend for Zymeworks's R&D?
- Over 2 years (2022 to 2024), Zymeworks's R&D has grown at a -19.7% compound annual growth rate (CAGR), from $208.6M to $134.62M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Zymeworks's r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude